Antigonie is built by our personal experiences of loved ones we have lost to cancer. Antigonie is built for the people we love living in their memory and for those living lives after cancer and for those living lives with cancer.
Antigonie is built by our shared belief that cancer treatment can and must be different: smarter, kinder, and curative.
Dr. Katherine Bridge is a highly respected leader in the field of molecular oncology. With 15 years of deep expertise in dissecting oncogenic molecular mechanisms, her laboratory is renowned for defining how aberrant RNA expression programs cause both solid and hematological cancers. Her stellar academic track record includes both a Wellcome Trust-funded Senior Postdoctoral Fellowship and the prestigious Kay Kendall Leukemia Fund Fellowship award. Since establishing her own research group in the historic city of York, UK, Dr. Bridge has successfully raised over £2M since 2021 from highly respected bodies including the Royal Society, Wellcome Trust, Medical Research Council, and Blood Cancer UK. This scientific and fundraising prowess provides Antigonie with a critical edge in translating foundational discoveries into viable commercial therapeutics. As CEO, Dr. Bridge sets the strategic direction, champions investor relations, and ensures operational execution aligns with the company’s moral mission to achieve curative eradication of hematologic malignancies through mutant-selective gene therapy.
Dr. Cathy Hawley is an immunologist and hematologist with an outstanding track record in high parameter hematopoietic cell analysis and characterization. She specializes in translating fundamental hematopoietic cell biology into pre-clinical in vivo model systems, enabling the integral component of Antigonie’s platform technology to enable delivery of our RNA therapeutics to HSPCs in the bone marrow. As CSO, Dr Hawley’s scientific leadership and rigor set the tone for Antigonie’s therapeutics: built on scientific excellence, with precision and purpose in mind.
